High suPAR and Low Blood Eosinophil Count are Risk Factors for Hospital Readmission and Mortality in Patients with COPD

References

• GOLD. Global strategy for the diagnosis, management, and prevention of COPD update 2019 2019 Available from: http://goldcopd.org. Accessed 15, 2019.
   Google Scholar
• LøkkeA, HilbergO, TønnesenP, IbsenR, KjellbergJ, JennumP. Direct and indirect economic and health consequences of COPD in Denmark: a national register-based study: 1998–2010. BMJ Open. 2014;4(1):e004069. doi:10.1136/bmjopen-2013-004069
   PubMed Web of Science ®Google Scholar
• DonaldsonGC, SeemungalTAR, BhowmikA, WedzichaJA. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57(10):847–852. doi:10.1136/thorax.57.10.84712324669
   PubMed Web of Science ®Google Scholar
• GuerreroM, CrisafulliE, LiapikouA, et al. Readmission for acute exacerbation within 30 days of discharge is associated with a subsequent progressive increase in mortality risk in COPD patients: a long-term observational study. PLoS One. 2016;11(3):e0150737. doi:10.1371/journal.pone.015073726943928
   PubMed Web of Science ®Google Scholar
• MüllerovaH, MaselliDJ, LocantoreN, et al. Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. Chest. 2015;147(4):999–1007. doi:10.1378/chest.14-065525356881
   PubMed Web of Science ®Google Scholar
• LomholtFK, LaulundAS, BjarnasonNH, JørgensenHL, GodtfredsenNS. Meta-analysis of routine blood tests as predictors of mortality in COPD. Eur Clin Respir J. 2014;1(1):24110. doi:10.3402/ecrj.v1.24110
   PubMedGoogle Scholar
• RasmussenLJH, LadelundS, HauptTH, et al. Soluble urokinase plasminogen activator receptor (suPAR) in acute care: a strong marker of disease presence and severity, readmission and mortality. A retrospective cohort study. Emerg Med J. 2016;33(11):769–775. doi:10.1136/emermed-2015-20544427590986
   PubMed Web of Science ®Google Scholar
• Eugen-OlsenJ, AndersenO, LinnebergA, et al. Circulating soluble urokinase plasminogen activator receptor predicts cancer, cardiovascular disease, diabetes and mortality in the general population. J Intern Med. 2010;268(3):296–308. doi:10.1111/j.1365-2796.2010.02252.x20561148
   PubMed Web of Science ®Google Scholar
• WestinO, RasmussenLJH, AndersenO, BuchE, OlsenJE, FribergJ. Soluble Urokinase Plasminogen Activator Receptor (suPAR) as a predictor of incident atrial fibrillation. J Atr Fibrillation. 2018;10:1801. doi:10.4022/jafib.180129988279
   PubMedGoogle Scholar
• ZhangY, XiaoW, JiangY, et al. Levels of components of the urokinase-type plasminogen activator system are related to chronic obstructive pulmonary disease parenchymal destruction and airway remodelling. J Int Med Res. 2012;40(3):976–985. doi:10.1177/14732300120400031622906270
   PubMed Web of Science ®Google Scholar
• GussenH, HohlsteinP, BartneckM, et al. Neutrophils are a main source of circulating suPAR predicting outcome in critical illness. J Intensive Care. 2019;7(1):26. doi:10.1186/s40560-019-0381-531061709
   PubMed Web of Science ®Google Scholar
• PliyevBK. Activated human neutrophils rapidly release the chemotactically active D2D3 form of the urokinase-type plasminogen activator receptor (uPAR/CD87). Mol Cell Biochem. 2009;321(1–2):111–122. doi:10.1007/s11010-008-9925-z18830568
   PubMed Web of Science ®Google Scholar
• CanÜ, GüzelantA, YerlikayaFH, YosunkayaŞ. The role of serum soluble urokinase-type plasminogen activator receptor in stable chronic obstructive pulmonary disease. J Investig Med. 2014;62(7):938–943. doi:10.1097/JIM.0000000000000105
   PubMed Web of Science ®Google Scholar
• GodtfredsenNS, JørgensenDV, MarsaaK, et al. Soluble urokinase plasminogen activator receptor predicts mortality in exacerbated COPD. Respir Res. 2018;19(1):97. doi:10.1186/s12931-018-0803-229783959
   PubMed Web of Science ®Google Scholar
• Ponce-GallegosMA, Ramírez-VenegasA, Falfán-ValenciaR. Th17 profile in COPD exacerbations. Int J Chron Obstruct Pulmon Dis. 2017;12:1857–1865. doi:10.2147/COPD.S13659228694696
   PubMed Web of Science ®Google Scholar
• KangHS, RheeCK, KimSK, et al. Comparison of the clinical characteristics and treatment outcomes of patients requiring hospital admission to treat eosinophilic and neutrophilic exacerbations of COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:2467–2473. doi:10.2147/COPD.S11607227757029
   PubMed Web of Science ®Google Scholar
• TashkinDP, WechslerME. Role of eosinophils in airway inflammation of chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2018;13:335–349. doi:10.2147/COPD.S15229129403271
   PubMed Web of Science ®Google Scholar
• Vedel-KroghS, NielsenSF, LangeP, VestboJ, NordestgaardBG. Blood eosinophils and exacerbations in chronic obstructive pulmonary disease. The copenhagen general population study. Am J Respir Crit Care Med. 2016;193(9):965–974. doi:10.1164/rccm.201509-1869OC26641631
   PubMed Web of Science ®Google Scholar
• PedersenCB. The Danish civil registration system. Scand J Public Health. 2011;39(7_suppl):22–25. doi:10.1177/140349481038796521775345
   PubMed Web of Science ®Google Scholar
• HauptTH, PetersenJ, EllekildeG, et al. Plasma suPAR levels are associated with mortality, admission time, and Charlson Comorbidity Index in the acutely admitted medical patient: a prospective observational study. Crit Care. 2012;16(4):R130. doi:10.1186/cc1143422824423
   PubMed Web of Science ®Google Scholar
• QuanH, LiB, CourisCM, et al. Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol. 2011;173(6):676–682. doi:10.1093/aje/kwq43321330339
   PubMed Web of Science ®Google Scholar
• WatzH, TetzlaffK, WoutersEFM, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med. 2016;4(5):390–398. doi:10.1016/S2213-2600(16)00100-427066739
   PubMed Web of Science ®Google Scholar
• YunJH, LambA, ChaseR, et al. Blood eosinophil count thresholds and exacerbations in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2018;141(6):2037–2047.e10. doi:10.1016/j.jaci.2018.04.01029709670
   PubMed Web of Science ®Google Scholar
• YoudenWJ. Index for rating diagnostic tests. Cancer. 1950;3(1):32–35. doi:10.1002/1097-0142(1950)3:1<32::aid-cncr2820030106>3.0.co;2-315405679
   PubMed Web of Science ®Google Scholar
• GumusA, AltintasN, CinarkaH, et al. Soluble urokinase-type plasminogen activator receptor is a novel biomarker predicting acute exacerbation in COPD. Int J Chron Obstruct Pulmon Dis. 2015;10:357–365. doi:10.2147/COPD.S7765425709430
   PubMed Web of Science ®Google Scholar
• PortelliMA, SiedlinskiM, StewartCE, et al. Genome-wide protein QTL mapping identifies human plasma kallikrein as a post-translational regulator of serum uPAR levels. FASEB J. 2014;28(2):923–934. doi:10.1096/fj.13-24087924249636
   PubMed Web of Science ®Google Scholar
• WangH, YangT, LiD, et al. Elevated circulating PAI-1 levels are related to lung function decline, systemic inflammation, and small airway obstruction in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2016;11:2369–2376. doi:10.2147/COPD.S10740927713627
   PubMed Web of Science ®Google Scholar
• BöcskeiRM, BenczúrB, LosonczyG, et al. Soluble urokinase-type plasminogen activator receptor and arterial stiffness in patients with COPD. Lung. 2019;1–9. doi:10.1007/s00408-019-00211-w.30361764
   PubMed Web of Science ®Google Scholar
• CoventryPA, GemmellI, ToddCJ. Psychosocial risk factors for hospital readmission in COPD patients on early discharge services: a cohort study. BMC Pulm Med. 2011;11(1):49. doi:10.1186/1471-2466-11-4922054636
   PubMed Web of Science ®Google Scholar
• ShahT, ChurpekMM, Coca PerraillonM, KonetzkaRT. Understanding why patients with COPD get readmitted: a large national study to delineate the Medicare population for the readmissions penalty expansion. Chest. 2015;147(5):1219–1226. doi:10.1378/chest.14-218125539483
   PubMed Web of Science ®Google Scholar
• StällbergB, JansonC, LarssonK, et al. Real-world retrospective cohort study ARCTIC shows burden of comorbidities in Swedish COPD versus non-COPD patients. NPJ Prim Care Respir Med. 2018;28(1):33. doi:10.1038/s41533-018-0101-y30202023
   PubMed Web of Science ®Google Scholar
• SchultzM, RasmussenLJH, KallemoseT, et al. Availability of suPAR in emergency departments may improve risk stratification: a secondary analysis of the TRIAGE III trial. Scand J Trauma Resusc Emerg Med. 2019;27(1):43. doi:10.1186/s13049-019-0621-730975178
   PubMed Web of Science ®Google Scholar
• CasanovaC, CelliBR, De-TorresJP, et al. Prevalence of persistent blood eosinophilia: relation to outcomes in patients with COPD. Eur Respir J. 2017;50. doi:10.1183/13993003.01162-2017.
   Web of Science ®Google Scholar
• HastieAT, MartinezFJ, CurtisJL, et al. Association of sputum and blood eosinophil concentrations with clinical measures of COPD severity: an analysis of the SPIROMICS cohort. Lancet Respir Med. 2017;5(12):956–967. doi:10.1016/S2213-2600(17)30432-029146301
   PubMed Web of Science ®Google Scholar
• LiQ, LarivéeP, CourteauJ, et al. Greater eosinophil counts at first COPD hospitalization are associated with more readmissions and fewer deaths. Int J Chron Obstruct Pulmon Dis. 2019;14:331–341. doi:10.2147/COPD.S18737530787603
   PubMed Web of Science ®Google Scholar
• PascoeS, LocantoreN, DransfieldMT, BarnesNC, PavordID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med. 2015;3(6):435–442. doi:10.1016/S2213-2600(15)00106-X25878028
   PubMed Web of Science ®Google Scholar
• RocheN, ChapmanKR, VogelmeierCF, et al. Blood eosinophils and response to maintenance chronic obstructive pulmonary disease treatment. Data from the FLAME trial. Am J Respir Crit Care Med. 2017;195(9):1189–1197. doi:10.1164/rccm.201701-0193OC28278391
   PubMed Web of Science ®Google Scholar
• Rahimi-RadMH, AsgariB, HosseinzadehN, EishiA. Eosinopenia as a marker of outcome in acute exacerbations of chronic obstructive pulmonary disease. Maedica (Buchar). 2015;10(1):10–13.26225143
   PubMedGoogle Scholar
• HollandM, AlkhalilM, ChandromouliS, JanjuaA, BaboresM. Eosinopenia as a marker of mortality and length of stay in patients admitted with exacerbations of chronic obstructive pulmonary disease. Respirology. 2010;15(1):165–167. doi:10.1111/j.1440-1843.2009.01651.x19947999
   PubMed Web of Science ®Google Scholar
• SangwanV, ChaudhryD, MalikR. Dyspnea, eosinopenia, consolidation, acidemia and atrial fibrillation score and BAP-65 score, tools for prediction of mortality in acute exacerbations of chronic obstructive pulmonary disease: a comparative pilot study. Indian J Crit Care Med. 2017;21(10):671–677. doi:10.4103/ijccm.IJCCM_148_1729142379
   PubMed Web of Science ®Google Scholar
• HurstJR, VestboJ, AnzuetoA, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363(12):1128–1138. doi:10.1056/NEJMoa090988320843247
   PubMed Web of Science ®Google Scholar
• ChenY-WR, LeungJM, SinDD. A systematic review of diagnostic biomarkers of COPD exacerbation. PLoS One. 2016;11(7):e0158843. doi:10.1371/journal.pone.015884327434033
   PubMed Web of Science ®Google Scholar
• HauptTH, KallemoseT, LadelundS, et al. Risk factors associated with serum levels of the inflammatory biomarker soluble urokinase plasminogen activator receptor in a general population. Biomark Insights. 2014;9:91–100. doi:10.4137/BMI.S1987625574132
   PubMedGoogle Scholar
• PortelliMA, StewartCE, HallIP, BrightlingCE, SayersI. Cigarette smoke and the induction of urokinase plasminogen activator receptor in vivo: selective contribution of isoforms to bronchial epithelial phenotype. Am J Respir Cell Mol Biol. 2015;53(2):174–183. doi:10.1165/rcmb.2014-0296OC25490122
   PubMed Web of Science ®Google Scholar
• Eugen-OlsenJ, LadelundS, SørensenLT. Plasma suPAR is lowered by smoking cessation: a randomized controlled study. Eur J Clin Invest. 2016;46(4):305–311. doi:10.1111/eci.1259326799247
   PubMed Web of Science ®Google Scholar
• PisingerC, JørgensenT, ToftU. A multifactorial approach to explaining the stagnation in national smoking rates. Dan Med J. 2018;65(2):15.
   Web of Science ®Google Scholar
• SavranO, GodtfredsenN, SørensenT, JensenC, UlrikCS. COPD patients prescribed inhaled corticosteroid in general practice: based on disease characteristics according to guidelines? Chron Respir Dis. n.d.;16:1479973119867949. doi:10.1177/147997311986794931431060
   PubMed Web of Science ®Google Scholar
• HenochI, StrangS, LöfdahlC-G, Ekberg-JanssonA. Management of COPD, equal treatment across age, gender, and social situation? A register study. Int J Chron Obstruct Pulmon Dis. 2016;11:2681–2690. doi:10.2147/COPD.S11523827822030
   PubMed Web of Science ®Google Scholar
• KilicH, KokturkN, SariG, CakırM. Do females behave differently in COPD exacerbation? Int J Chron Obstruct Pulmon Dis. 2015;10:823–830. doi:10.2147/COPD.S7895225977604
   PubMed Web of Science ®Google Scholar
• DeMeoDL, RamagopalanS, KavatiA, et al. Women manifest more severe COPD symptoms across the life course. Int J Chron Obstruct Pulmon Dis. 2018;13:3021–3029. doi:10.2147/COPD.S16027030319250
   PubMed Web of Science ®Google Scholar